Ardelyx Presents Real-World Data at ASN Kidney Week 2026 for XPHOZAH

At ASN Kidney Week 2026, Ardelyx presented real-world data on XPHOZAH (tenapanor) showing that serum phosphate levels decreased in dialysis patients over six months, with adjusted mean reductions between 0.80 and 1.55 mg/dL. The company also discussed the challenges of managing hyperphosphatemia and its associated health risks. These findings support the clinical utility of XPHOZAH in improving phosphate control in patients.